循环中检测奈普利素源性BNP片段:对心衰靶向奈普利素抑制治疗的启示
本研究探讨奈普利素(NEP)切割B型利钠肽(BNP)产生的片段BNP-neo17,在大鼠模型和心衰患者血浆中的检测及意义。结果显示大鼠循环中BNP-neo17生成可被NEP抑制剂沙库巴曲阻断,患者血浆BNP-neo17浓度范围为0-37 pg/mL,且BNP-neo17/总BNP比值与总BNP无相关性,提示BNP-neo17可能反映NEP活性。
要点
- BNP-neo17由NEP切割活性BNP产生,其生成可被沙库巴曲阻断。
- 心衰患者血浆BNP-neo17浓度低,个体间变异大。
- BNP-neo17/总BNP比值与总BNP无相关性,或反映NEP活性。
核心结论
- BNP-neo17的形成依赖于NEP活性,可能反映NEP活性和利钠潜力,用于心衰治疗指导。
研究设计与样本
- 大鼠模型注射BNP,联合或不联合沙库巴曲抑制NEP,不同时间点检测血浆BNP-neo17。
- 检测32例心衰患者EDTA血浆样本中BNP-neo17和总BNP。
主要发现
- 大鼠循环中BNP-neo17生成可被NEP抑制阻止,注射后2分钟沙库巴曲组与对照组浓度差异最大达13.2倍。
- 32例心衰患者血浆BNP-neo17浓度范围为0-37 pg/mL(中位数5.4,四分位距0-9.1)。
- BNP-neo17/总BNP比值与总BNP浓度无相关性(r=-0.175,P=0.680),且个体间存在变异。
临床怎么用
- BNP-neo17或可作为反映NEP活性的生物标志物,辅助心衰靶向NEP抑制治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Entresto™ is a new heart failure (HF) therapy that includes the neprilysin (NEP) inhibitor sacubitril. One of the NEP substrates is B-type natriuretic peptide (BNP); its augmentation by NEP inhibition is considered as a possible mechanism for the positive effects of Entresto. We hypothesized that the circulating products of BNP proteolysis by NEP might reflect NEP impact on the metabolism of active BNP. We suggest that NEP-based BNP cleavage at position 17-18 results in BNP ring opening and formation of a novel epitope with C-terminal Arg-17 (BNP-neo17 form). In this study, we use a specific immunoassay to explore BNP-neo17 in a rat model and HF patient plasma. METHODS: We injected BNP into rats, with or without NEP inhibition with sacubitril. BNP-neo17 in plasma samples at different time points was measured with a specific immunoassay with neglectable cross-reactivity to intact forms. BNP-neo17 and total BNP were measured in EDTA plasma samples of HF patients. RESULTS: BNP-neo17 generation in rat circulation was prevented by NEP inhibition. The maximum 13.2-fold difference in BNP-neo17 concentrations with and without sacubitril was observed at 2 min after injection. BNP-neo17 concentrations in 32 HF patient EDTA plasma samples ranged from 0 to 37 pg/mL (median, 5.4; interquartile range, 0-9.1). BNP-neo17/total BNP had no correlation with total BNP concentration (with r = -0.175, P = 0.680) and showed variability among individuals. CONCLUSIONS: BNP-neo17 formation is NEP dependent. Considering that BNP-neo17 is generated from the active form of BNP by NEP, we speculate that BNP-neo17 may reflect both the NEP activity and natriuretic potential and serve for HF therapy guidance.
引用
- Feygina EE, Artemieva MM, Postnikov AB, et al. Detection of Neprilysin-Derived BNP Fragments in the Circulation: Possible Insights for Targeted Neprilysin Inhibition Therapy for Heart Failure. Clin Chem. 2019. PMID: 31307994. doi:10.1373/clinchem.2019.303438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。